The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Podcasting since 2024 • 21 episodes
The BioCentury Show
Latest Episodes
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular decisions at the start of his tenure and a surge in cancer drug development over the la...
•
Season 3
•
Episode 71
•
41:44
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were ...
•
Season 3
•
Episode 70
•
33:56
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a unique case that is unlikely to set a precedent, former CMS CMO Lee Fleisher told BioCentury. “I do...
•
Season 3
•
Episode 69
•
34:36
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particular...
•
Season 3
•
Episode 68
•
35:08
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regul...
•
Season 3
•
Episode 67
•
28:51
Contributors
.jpg)
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
